The Spark, Medicon Village
223 81 Lund, Sweden
Our vision is to limit the spread of infectious diseases worldwide by creating an accurate, easy-to-use, cost-efficient, quick, and universal diagnostics platform, Panviral, for diagnosing essentially any type of infectious disease with the same accuracy as todays PCR based technologies. Diagonal Bio’s patented technology can also be used for identification of genetic markers for the less regulated market segments, LAMPlify®.
Diagonal Bio started with a short series of WhatsApp messages between two of the Swedish-based company’s founders.
In the shadows of the COVID-19 pandemic, these messages simply asked why molecular biology and electrochemistry hadn’t been combined to speed up the accurate identification of genetic markers to fight disease?
This application of diagonal thinking – using linear and lateral thinking to develop and realize new ideas– gave rise to Diagonal Bio. This same dynamism and diagonal thinking approach has continued to drive the rapid development of Diagonal Bio since its foundation in 2020.
Based on the patented technology, Diagonal Bio is developing two distinct systems targeting different market segments where there is a clear need for an easy-to-use and highly portable way to deliver fast and accurate identification of genetic markers in DNA and RNA.
A System that is CE-marked according to the Low Voltage Directive (LVD), LAMPlify®, which means that LAMPlify® meets the relevant requirements and standards according to the European Union (EU) directives and regulations, enabling Diagonal Bio to commercialize LAMPlify® in the less regulated market segments, for example, using LAMPlify® as a tool for fast, reliable, and cost-effective method for identifying genetic markers in research laboratories (Research Use Only), and a System intended for CE-marking according EU-IVDR and/or US-FDA, PANVIRAL®, for use as a universal in-vitro diagnostic platform.
Diagonal Bio’s growth has been supported by a management and Board with experience in diagnostics, biotechnology, medical technology, and business development focused on bringing innovative ideas and products to market globally.
Located in Medicon Village, Lund, Sweden, Diagonal Bio collaborates with leading Key Opinion Leaders (KOLs), clinicians and researchers throughout Sweden and Denmark.
It is also able to leverage the network of expertise in research and life science entrepreneurship that Medicon Village and the Medicon Valley Alliance (MVA) provides.
Diagonal Bio is listed on Nasdaq Stockholm First North under the ticker symbol DIABIO.